Comparison of Calcitriol and Metformin Effects on Clinical and Metabolic Consequences of Polycystic Ovary Syndrome

Document Type : Original Article

Authors

1 Assistant professor of endocrinology, Endocrine Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Fellow of endocrinology, Endocrine Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Assistant professor of radiology, Endocrine Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Associated professor of Vital Statistics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction: Prevalence of polycystic ovarian syndrome (PCOS) in reproductive age women is about 10 %. There is a lot of morbidity due to this syndrome. Vitamin D deficiency is a common problem in the world and especially in Iran. Because of probable role of activated vitamin D on induction of insulin secretion and reduction in insulin resistance and the effect of hyperinsulinemia on elevation of free androgens; we designed to evaluate the effect of active form of vitamin D on control of PCOS clinical and metabolic complications.
Methods: This clinical trial study was carried out in Ghaem hospital. 51 untreated PCOS patients randomly were divided into three groups. Treatment with calcitriol (0.5mg), metformin (1000 mg) and placebo were started for each group for three month. After three month assessment for improvement in clinical (improvement of ovulation) and metabolic status (fasting blood glucose, glucose tolerance test, insulin resistance and androgen levels) were performed.
 
Results: Only 22.9% of patients had sufficient vitamin D levels (>30 ng/ml).Treatment with metformin significantly decreased weight (p=0.027), insulin level (p=0.043), insulin resistance (p=0.048) and BMI (p=0.019). Systolic blood pressure and PTH significantly decreased after calcitriol therapy (p=0.029, 0.009 respectively). An improvement in ovulation was detected after calcitriol treatment and 7 patients without ovulation demonstrated ovulation features after treatment with calcitriol. Resumption of ovulation was observed in treatment with metformin and placebo but this changes were significantly more evident in calcitriol group (p=0.02).
 
Conclusion: It seems that treatment with calcitriol may be effective in management of PCOS and it may be better in ovulation induction than metformin therapy.

Keywords

References

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the
polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 Jun;89(6):2745-
9.PMID: 15181052
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary
syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. PMID: 14688154
3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24;352(12):1223-36.PMID: 15788499
4. McCarty MF. Poor vitamin D status may contribute to high risk for insulin resistance, obesity, and
cardiovascular disease in Asian Indians. Med Hypotheses. 2009; 72(6):647-51.PMID: 19217213
5. Gannage-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G. Vitamin D in relation to metabolic
risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol.
2009;160(6):965-8.PMID: 19289535
6. Major GC, Alarie F, Dore J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D
enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin
Nutr. 2007 Jan; 85(1):54-9.PMID: 17209177
7. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation
on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007 Apr; 30(4):980-
6.PMID; 17277040
8. Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, et al. Low serum 25-hydroxyvitamin D
concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome.
Experimental and Clinical Endocrinology and Diabetes. 2006;114(10):577-83.PMID: 17177140
9. Kotsa K, Yavropoulou MP, Anastasiou O, Yovos JG. Role of vitamin D treatment in glucose metabolism in
polycystic ovary syndrome. Fertil Steril. 2009 Sep;92(3):1053-8.PMID: 18930208
10. Velazquez EM, et al: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin
resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and
pregnancy. Metabolism 1994; 43(5):647-654.PMID: 8177055
11. Lord JM, et al: Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiroinositol)
for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;CD003053.PMID: 12917943
12. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, et al. Association of hypovitaminosis D
with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009 Oct;161(4):575-
82.PMID: 19628650
13. Wortsman J., Matsuoka LY, Chen TC, LU Z, Holick MF. Decreased bioavailability of vitamin D in
obesity. American Journal of Clinical Nutrition. 2000;72:690-93.PMID: 10966885
14. Compston JE, Vedi S, Ledger JE, Webb A, Gazet JC, Pilkington TR. Vitamin D status and bone
histomorphometery in grass obesity. American Journal of Clinical Nutrition.1981:34;2359-63.PMID:
7304477
15. Mahmoudi T, Gourabi H, Ashrafi M, Yazdi RS, Ezabadi Z. Calciotropic hormones, insulin resistance, and
the polycystic ovary syndrome. Fertil Steril. 2010 Mar 1;93(4):1208-14.PMID: 19230880
 
16. Major GC, Alarie F, Dore J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D
enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin
Nutr. 2007 Jan; 85(1):54-9.PMID: 17209177
17. ai K, Need AG, Horowitz M, Chapman IM. Glucose tolerance and vitamin D: effects of treating vitamin D
deficiency. Nutrition. 2008 Oct;24(10):950-6. PMID: 18653316
18. Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation
in the polycystic ovarian syndrome. Steroids. 1999 Jun;64(6):430-5.PMID: 10433180
19. Rashidi B, Haghollahi F, Tehranian N, Shariat M, Zayerii F, Bagheri M, et al. Therapeutic effects of
vitamin D and calcium in patients with polycystic ovary syndrome. Journal of Fertility and Infertility.
2006;7(3):225-33
20. Racowsky C. The releasing action of calcium upon cyclic AMP-dependent meiotic arrest in hamster
oocytes. J Exp Zool. 1986 Aug;239(2):263-75.PMID: 2427641
21. Das M, Djahanbakhch O, Hacihanefioglu B, Saridogan E, Ikram M, Ghali L, et al. Granulosa cell survival
and proliferation are altered in polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Mar;93(3):881-
7.PMID: 18073308
22. Lou YR, Murtola T, Tuohimaa P. Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin
D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells. J Steroid
Biochem Mol Biol. 2005 Feb;94(1-3):151-7.PMID: 15862960
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 14, Issue 8 - Serial Number 8
February 2012
Pages 16-24

Files

Share

How to cite

Statistics